Sedgefield, UK. November 2012 – Market leading 3D cell culture company, Reinnervate Ltd, today announced that it has launched and commenced shipments of Alvetex® Scaffold 96 well plates to customers.
“We are very pleased that the pent up demand for Alvetex Scaffold in a 96 well plate format has meant we have immediately received orders from several Pharmaceutical customers and an Oncology-focused CRO,” commented Richard Rowling, Commercial Director of Reinnervate. “The work we have done with customers over the last 12 months has clearly demonstrated the need for a simple and reproducible 3D cell culture platform and now with a 96 well plate format, we can push deeper into the drug discovery and screening markets.”
Prof. Stefan Przyborski, founder and CSO of Reinnervate described a typical application in cancer cell cyto-toxicity testing; “The Alvetex Scaffold 96 well plates allow scientists to grow tumour cells in a way that better mimics the way these cells grow in vivo. It is then very simple to test the cytotoxic effect of novel or existing anti-cancer compounds using standard cell health assays such as MTT, XTT, Cell Titer-Glo® and many others. We can then easily retrieve RNA and protein from the drug treated cells to study mechanism of action and look for biomarkers.” He went on to say, “We have also shown that the Alvetex Scaffold 96 well plates work seamlessly with automated platforms such as the Tecan Freedom EVO 200®.”
For further information, please contact: email@example.com
About Reinnervate Ltd
Reinnervate is an innovative life sciences company dedicated to making routine 3D cell culture a reality for researchers in academia and in the pharmaceutical and related industries.
Reinnervate develops, manufactures and sells products for 3D cell culture. During 2012 Reinnervate has launched several new formats including 24 and 96 well plates and developed specialist applications for scientists working in the fields of cancer research, cell migration/invasion and stem cell culture/expansion.
Reinnervate was founded in 2002 based on the pioneering research of Professor Stefan Przyborski and his lab at Durham University, UK, and is funded by NorthStar Equity Investors (NSEI), management and private investors.
Alvetex Scaffold is a unique polystyrene material that provides a robust and inert scaffold for cells to grow and form complex 3D structures in vitro, mimicking the normal growth and formation of tissues in the body. Reinnervate has extensively tested and validated Alvetex Scaffold with a large number of cell types, including liver, skin, cancer and stem cells, all of which have important applications in basic research into cell development, disease modelling and drug safety screening.
Alvetex Scaffold has been launched globally in several formats: a 12-well culture plate, 24-well culture plate, 96 well plate, 6-well and 12-well inserts. These formats enable scientists to construct different 3D cell culture models and assays. These include screening of novel drugs / drug combinations on 3D culture and co-culture models, co-culture to study cell-cell or cell-matrix interactions, the growth of cells at the air-liquid interface and the long-term culture of cells.
Alvetex Scaffold was voted as one of the top 100 innovative products of 2011 at the R&D 100 awards and was named among the winners of The Scientist magazine’s “Top 10 Life Science Innovations of 2010.”
Note: Reinnervate Ltd (County Durham, England) was acquired by REPROCELL Inc (Yokohama, Japan) in August 2014. Biopta Ltd (Glasgow, Scotland) was acquired by REPROCELL in November 2015. REPROCELL Europe Ltd was established by merging Reinnervate and Biopta in June 2016.